Quantedge Capital Pte Ltd increased its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 295.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,800 shares of the company’s stock after buying an additional 70,800 shares during the quarter. Harmony Biosciences accounts for about 0.4% of Quantedge Capital Pte Ltd’s investment portfolio, making the stock its 15th largest position. Quantedge Capital Pte Ltd owned 0.16% of Harmony Biosciences worth $3,722,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently bought and sold shares of HRMY. Chase Investment Counsel Corp bought a new position in Harmony Biosciences during the 2nd quarter valued at about $1,820,000. Canada Pension Plan Investment Board acquired a new position in Harmony Biosciences in the second quarter valued at about $1,209,000. The Manufacturers Life Insurance Company bought a new stake in Harmony Biosciences during the second quarter worth about $870,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Harmony Biosciences during the second quarter worth approximately $1,656,000. Finally, Point Nemo Capital LLC acquired a new stake in shares of Harmony Biosciences during the third quarter worth approximately $1,432,000. 86.23% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other news, insider Kumar Budur sold 35,852 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $43.05, for a total value of $1,543,428.60. Following the completion of the transaction, the insider owned 13,115 shares in the company, valued at $564,600.75. This represents a 73.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 72,406 shares of company stock valued at $3,108,520 over the last 90 days. Insiders own 11.00% of the company’s stock.
Harmony Biosciences Price Performance
Shares of HRMY stock opened at $32.96 on Tuesday. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.90 and a 1 year high of $43.49. The firm’s 50 day moving average is $38.46 and its 200-day moving average is $34.60. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of 11.19, a PEG ratio of 0.36 and a beta of 1.00. The company has a current ratio of 3.44, a quick ratio of 3.42 and a debt-to-equity ratio of 0.12.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.81 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.28). Harmony Biosciences had a net margin of 18.05% and a return on equity of 18.55%. The company had revenue of $268.92 million for the quarter, compared to the consensus estimate of $272.05 million. During the same period last year, the company earned $1.08 earnings per share. Harmony Biosciences’s revenue for the quarter was up 12.3% compared to the same quarter last year. Sell-side analysts forecast that Harmony Biosciences Holdings, Inc. will post 3.55 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
HRMY has been the topic of several recent analyst reports. Ladenburg Thalmann & Co. Inc. began coverage on Harmony Biosciences in a report on Thursday, October 15th. They issued a “buy” rating and a $55.00 target price on the stock. UBS Group restated a “neutral” rating and set a $37.00 price target on shares of Harmony Biosciences in a research report on Wednesday, August 5th. Wolfe Research initiated coverage on Harmony Biosciences in a report on Wednesday, August 26th. They set an “outperform” rating and a $60.00 price target for the company. Zacks Research downgraded Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Friday. Finally, Oppenheimer reissued an “outperform” rating on shares of Harmony Biosciences in a research note on Thursday, September 24th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $48.00.
Check Out Our Latest Analysis on HRMY
Harmony Biosciences Profile
Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs. Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S. market.
Read More
- Five stocks we like better than Harmony Biosciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report).
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
